Survivors on Science: Pass the Hormones Hold The Chemo? Maybe, for some!

Earlier this month we celebrated National Cancer Survivors Day and then learned that some 70% of breast cancer patients may be able to skip chemo - what a way to kick off June! The TAILORx trial, or more formally Trial Assigning Individualized Options for Treatment (Rx) trial, used a molecular test to examine tumors and assess 21 genes connected with breast cancer recurrence to determine the most appropriate post-operative treatment for women with hormone receptor (HR)-positive, HER2-negative, axillary lymph node–negative breast cancer - a.k.a. the most common form of breast cancer. The study was comprehensive, enrolling a whopping 10,273 women with this type of breast cancer at more than 1,

Recent Posts
Archive

Find us on social...

Eye of the Survivor® 2020

  • Facebook Social Icon
  • Instagram Social Icon
  • Twitter Social Icon